SCHEMBL2921735

SCHEMBL2921735

O=C(Nc1ccc2nc(CN3CCOCC3)ccc2c1)c1ccc(-c2ccc(F)cc2)cc1

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 8/20 0.84
HTR2C P28335 6/20 0.84
LMNA P02545 3/20 0.60
ALDH1A1 P00352 2/20 0.60
RECQL P46063 1/20 0.60
RAB9A P51151 5/20 0.60
NPC1 O15118 4/20 0.60
ADORA2A P29274 1/20 0.53
HIF1A Q16665 1/20 0.52
EPAS1 Q99814 1/20 0.52
KMT2A Q03164 2/20 0.51
MEN1 O00255 1/20 0.51
SMN1; SMN2 Q16637 2/20 0.50
TP53 P04637 2/20 0.50
CD274 Q9NZQ7 1/20 0.50
THRB P10828 1/20 0.50
FAAH O00519 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
TSHR P16473 1/20 0.49
POLB P06746 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2926863 0.91 MCHR1 (0.69) MCHR1HTR2CLMNAALDH1A1RECQL
SCHEMBL2927594 0.91 MCHR1 (1.00) MCHR1HTR2CLMNAALDH1A1ADORA2A
SCHEMBL2920492 0.90 MCHR1 (0.68) MCHR1HTR2CLMNAALDH1A1RAB9A
SCHEMBL2926869 0.90 MCHR1 (0.98) MCHR1HTR2CADORA2ASMN1; SMN2FAAH
SCHEMBL2925567 0.82 HTR2C (0.73) MCHR1HTR2CLMNAALDH1A1ADORA2A
SCHEMBL2921144 0.82 MCHR1 (0.83) MCHR1HTR2CRAB9ANPC1FAAH
SCHEMBL13177222 0.82 HTR2C (0.73) MCHR1HTR2CLMNAALDH1A1RECQL
SCHEMBL2926361 0.81 MCHR1 (0.81) MCHR1HTR2CSMN1; SMN2FAAH
SCHEMBL2926586 0.81 MCHR1 (0.81) MCHR1HTR2CADORA2ASMN1; SMN2
SCHEMBL2923190 0.81 MCHR1 (0.64) MCHR1HTR2CADORA2AHIF1AEPAS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1285651-B1 MELANIN CONCENTRATING HORMONE ANTAGONISTS TAKEDA PHARMACEUTICAL (JP) 2010-09-01 EP disclosed
EP-1285651-B1 MELANIN CONCENTRATING HORMONE ANTAGONISTS TAKEDA PHARMACEUTICAL (JP) 2010-09-01 EP disclosed
US-6930185-B2 Melanin-concentrating hormone antagonist TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2005-08-16 US disclosed
US-20040077628-A1 Melanin-concentrating hormone antagonist TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-04-22 US disclosed
EP-1285651-A1 MELANIN CONCENTRATING HORMONE ANTAGONISTS Takeda Chemical Industries, Ltd. (JP) 2003-02-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077628-A1 Melanin-concentrating hormone antagonist MCHR1, MC1R, MCHR2 MCHR1 1/4885HTR2C 107/4885LMNA 4113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.